Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Estuary Biotherapeutics raises $93 million in Series A financing, led by RA Capital Management, to develop targeted gene therapies for kidney disease.
Amount Raised
$93 Million
Round Type
Series A
Investors
Description
Estuary Biotherapeutics, which focuses on genetic medicines for serious kidney diseases, announced its launch with $103 million in total committed financing. The Series A funding of $93 million was led by RA Capital Management. Other investors included Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, and the National Kidney Foundation Innovation Fund. The funding will support the development of targeted gene therapies for kidney disease.
Fundz sees it the moment Estuary Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansEstuary Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.